SAN DIEGO, Oct. 26 /PRNewswire/ -- Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.
The Company's orphan drug program is focused on satisfying an unmet medical need for the treatment of polyomavirus infections. The human polyomaviruses, JC and BK, are responsible for fatal disorders of the brain and kidney, to include progressive multifocal leukoencephalopathy (PML), an AIDS-defining disease that also afflicts patients on autoimmune disorder treatments for MS, lupus and arthritis. IkT-001 has a mechanism of action that can suppress polyomavirus reactivation in viral reservoirs, even in patients who are immune compromised. In some cases, a therapeutic vaccine effect can be realized with this product.